close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.590 -0.060 (-1.64%)
Streaming Delayed Price Updated: 3:16 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Earnings Preview ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Management will also participate in two upcoming healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Evaluating Myriad Genetics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation ↗
Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. 
Via Benzinga
News headline image
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
The Myriad Collaborative Research Registry has more than one million patient cases 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx... 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. 
Via Benzinga
News headline image
Myriad Genetics to Participate in Stephens Annual Investment Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
AerSale, Topgolf Callaway Brands, Digital Turbine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures traded mostly higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
News headline image
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today